In this second part of our discussion with Don M. Benson, MD, PhD, from our recent Institute for Value-Based Medicine® event in Cleveland, Ohio, he explains how his ultimate goal for his patients is for them to live as long and as well as possible.
In our ongoing discussion with Don M. Benson, MD, PHD, The Ohio State University Comprehensive Cancer Center, who moderated the multiple myeloma panel discussion at our recent Institute for Value-Based Medicine® event in Cleveland, Ohio, he explains what are his top priorities for his patients throughout their treatment journey for multiple myeloma and how caring for them is a true partnership.
As a hematologist-oncologist, Benson has cared for patients at James Cancer Hospital for 22 years, where he strives to enable his patients to live as long and as well as possible, he explains in this clip.
“We make it work,” he says, “and that's amazing because, again, we didn't do that 20 years ago."
The transcript has been lightly edited for clarity.
Transcript
What factors should guide the choice between traditional transplant options and newer immunotherapy approaches for newly diagnosed or relapsed disease?
When I meet somebody with myeloma, my goal is for them to live as long as possible and as well as possible. Leaving the complexities aside for a second, the principal goal of induction treatment is to alleviate suffering, get symptoms under control, get the disease in remission. I tell my patients, we're going to play offense, we're going to take the ball. We're playing offense, and the goal is a complete remission. The goal is to get you back to life before you heard those words that you have myeloma.
We’re blessed. We can achieve that now for the vast majority of people within a few months.The challenge really isn't getting the disease under control nowadays, it's doing it in a way to minimize toxicities, minimize side effects, even down to things like time. How long are you in the clinic? How long are you away from your life? These are things that we never would have thought of 20 years ago. So I think starting with principles and then moving forward, once the disease is in remission.
We talk a little bit about this shared decision-making model of, we have a panoply of options available. What makes sense for you with your myeloma right now? Realizing that that answer might be different 2 years from now or 5 years from now. But what can we do right now to stay on our true north, that I want you to live as long as possible and as well as possible. And for some people, that's a transplant.For some people, that's maybe a CAR [chimeric antigen receptor] T cell. For some people, that might be stopping treatment and just taking a maintenance drug.
What strategies can be implemented to support caregivers and enhance patient engagement throughout this journey?
I can speak to my perspective at a referral center that the vast majority of people with myeloma are receiving care in community settings. Oftentimes, when we get involved at a referral center, at an academic center, there's potentially a question about transplant eligibility, about eligibility for a BiTE [bispecific T-cell engager] or a CAR T cell. But just as often, these are referrals that are like grassroots referrals, and it's often an adult child who's driving care.It's not the patient who's maybe 75 or 80 years old, it's an adult child who's gotten on the internet, who's going to support groups, who's done his or her homework, and is saying, “Mom, I really think it's worth the drive to this center. Not that we are unhappy with our care, not that we disagree with our care, but this is a rare cancer. Maybe it would make sense to have somebody look at your case and meet you once, who does it for a living, who sees it every day.”
And I'm all about that. I think that's so important. Myeloma is a rare cancer, and I think the more that—the patient, obviously—but the patient's family, their loved ones, and most often it's the adult children—it's actually usually the oldest daughter for what it's worth, who's taking time off work, who's finding childcare, who's making sacrifices to make sure mom or dad is getting the best care possible. And I see that as a partnership, and I truly see it as a shared decision-making model, because things that we would do for one person… I've had patients come in and say, “I got 400 acres of corn I have to harvest.” And I've had other people come in and say, “We have nonrefundable tickets for a cruise around Greece.”
And so we make it work. And that's amazing because, again, we didn't do that 20 years ago.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More